COMP <GO>
OCUL vs URGN // EV/EBITDA & P/E VALUATION
Ocular Therapeutix Inc. (NASDAQ) VS. UroGen Pharma Ltd. (NASDAQ) • 15-METRIC TALLY: OCUL 2
— URGN 4
■ METRIC PARITY
LAST: $7.31 (+0.27%) • MKT CAP: $1.61B
valuation
—
LAST: $33.48 (-0.80%) • MKT CAP: $1.64B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OCUL VS. URGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OCUL | URGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.30% | 88.70% | -1.40 | URGN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -13.51% | -9.94% | -3.57 | URGN | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -18.50% | 21.40% | -39.90 | URGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.31 | 0.20 | +4.11 | OCUL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.3 | 26.4 | +15.91 | OCUL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.61B | $1.64B | -$31.1M | URGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OCUL REV | URGN REV | OCUL GROSS % | URGN GROSS % | OCUL FCF | URGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $52.0M | $109.8M | 87.3% | 88.7% | -$216.9M | -$162.7M |
| FY 2024 | $63.7M | $90.4M | 91.2% | 90.2% | -$136.0M | -$97.1M |
| FY 2023 | $58.4M | $82.7M | — | — | -$70.2M | -$76.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OCUL // BETA —
URGN // BETA —